Joanna Zawitkowska1, Monika Lejman2, Agnieszka Zaucha-Prażmo1, Katarzyna Drabko1, Marcin Płonowski3, Joanna Bulsa4, Michał Romiszewski5, Agnieszka Mizia-Malarz6, Andrzej Kołtan7, Katarzyna Derwich8, Grażyna Karolczyk9, Tomasz Ociepa10, Magdalena Ćwiklińska11, Joanna Trelińska12, Joanna Owoc-Lempach13, Maciej Niedźwiecki14, Aleksandra Kiermasz15, Jerzy Kowalczyk1. 1. Department of Paediatric Haematology, Oncology and Transplantology, Medical University of Lublin, Lublin, Poland. 2. Department of Paediatric Haematology, Oncology and Transplantology, Genetic Diagnostic Laboratory, University Children's Hospital, Lublin, Poland. 3. Department of Paediatric Oncology, Haematology, Medical University of Białystok, Białystok, Poland. 4. Department of Paediatrics, Haematology and Oncology, Medical University of Zabrze, Zabrze, Poland. 5. Department of Haematology and Paediatrics, Children's Hospital, Warsaw, Poland. 6. Department of Paediatric Oncology, Haematology and Chemotherapy, Medical University of Katowice, Katowice, Poland. 7. Department of Paediatrics, Haematology and Oncology, Collegium Medicum of Bydgoszcz, Bydgoszcz, Poland. 8. Department of Paediatric Oncology, Haematology and Transplantology, Medical University of Poznań, Poznań, Poland. 9. Department of Paediatric Oncology and Haematology, Children's Hospital, Kielce, Poland. 10. Department of Paediatrics, Haematology and Oncology, Medical University of Szczecin, Szczecin, Poland. 11. Department of Paediatric Oncology and Haematology, Children's University Hospital, Kraków, Poland. 12. Department of Paediatrics, Oncology, Haematology and Diabetology, Medical University of Łódź, Łódź, Poland. 13. Department of Paediatric Transplantology, Oncology, Haematology, Medical University of Wrocław, Wrocław, Poland. 14. Department of Paediatrics, Haematology, Oncology and Endocrinology, Medical University of Gdańsk, Gdańsk, Poland. 15. Department of Paediatric Haematology and Oncology, Center of Paediatrics and Oncology, Chorzów, Poland.
Abstract
OBJECTIVE: The aim of this study was to analyse the clinical characteristics and outcome of children diagnosed with Ph+ ALL. MATERIAL AND METHODS: A total of 2591 newly diagnosed ALL children were treated in Poland between the years 2005 and 2017. Of those, 44 were diagnosed with Ph(+) ALL. The patients were treated according to protocols: ALL IC-BFM 2002 and 2009 (26 patients), EsPhALL (12 patients), initially ALL IC-BFM and then EsPhALL (6 patients). RESULTS: The median of follow-up in the observed group was 3 years. Overall survival (OS) and event-free survival (EFS) of Ph+ ALL group were 0.73 and 0.64. OS and EFS of patients after HSCT were 0.78 and 0.66, while without HSCT were 0.6 and 0.6, P = 0.27 and 0.63. OS was 0.8 for patients treated with chemotherapy plus imatinib and 0.61 for chemotherapy alone, P = 0.22, while EFS was 0.66 (imatinib therapy) and 0. 61 (without imatinib), P = 0.41. CONCLUSION: Our study suggests that adding imatinib to intensive chemotherapy seems to improve outcome. However, this study was limited by a small number of patients and a variety of chemotherapy regimens with or without imatinib.
OBJECTIVE: The aim of this study was to analyse the clinical characteristics and outcome of children diagnosed with Ph+ ALL. MATERIAL AND METHODS: A total of 2591 newly diagnosed ALL children were treated in Poland between the years 2005 and 2017. Of those, 44 were diagnosed with Ph(+) ALL. The patients were treated according to protocols: ALL IC-BFM 2002 and 2009 (26 patients), EsPhALL (12 patients), initially ALL IC-BFM and then EsPhALL (6 patients). RESULTS: The median of follow-up in the observed group was 3 years. Overall survival (OS) and event-free survival (EFS) of Ph+ ALL group were 0.73 and 0.64. OS and EFS of patients after HSCT were 0.78 and 0.66, while without HSCT were 0.6 and 0.6, P = 0.27 and 0.63. OS was 0.8 for patients treated with chemotherapy plus imatinib and 0.61 for chemotherapy alone, P = 0.22, while EFS was 0.66 (imatinib therapy) and 0. 61 (without imatinib), P = 0.41. CONCLUSION: Our study suggests that adding imatinib to intensive chemotherapy seems to improve outcome. However, this study was limited by a small number of patients and a variety of chemotherapy regimens with or without imatinib.
Authors: Reyna Aguilar Quispe; Elizabeth Marques Aguiar; Claudia Teresa de Oliveira; Ana Cristina Xavier Neves; Paulo Sérgio da Silva Santos Journal: Hematol Transfus Cell Ther Date: 2021-11-22